HWPC(SH:688799)2024-03-08 09:34Group 1: Company Overview - Warner Pharmaceutical is involved in the research and development of alternative products for endangered animal medicinal materials [1][2] - The company has established partnerships for research projects related to endangered animal medicinal materials [2] - The ZY022 project has completed preclinical research and is progressing to the next development phase [2] Group 2: Product Development - The Qianqing Granules, a Class 1 new traditional Chinese medicine, has completed Phase I clinical trials and is entering Phase II [3] - Bromovirin tablets have been approved and are now on the market, classified as a new chemical drug [4] - Faropenem sodium granules are included in the National Basic Medical Insurance Drug List for 2023 [4] Group 3: Financial Performance - In 2022, the company's formulation products generated revenue of 1.061 billion yuan, with major therapeutic areas including digestive, respiratory, anti-infection, and anti-anemia [5] - The company has 57 specialty chemical raw materials, with 41 products having an "A" registration status [6] - Revenue from raw materials and intermediates reached 207 million yuan in 2022 and 220 million yuan in the first three quarters of 2023 [6]